Sign up now and fund within 24h to get A$10.
Claim It Now
Stake logo

Avecho Biotechnology Limited

1 day chart

Get A$10 trading credit to start you off

Sign up and fund a new Stake AUS account and enjoy an extra A$10 trading credit on us.

Sign up and fund a new Stake AUS account and get A$10 bonus trading credit.

T&Cs apply
Claim now
Get A$10 trading credit to start you off

About AVE

Avecho Biotechnology Limited (AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM (Tocopherol Phosphate Mixture). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Major projects include delivering TPM enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM to cannabinoids.

Buy Australian shares starting with AVE. Invest today with a CHESS-sponsored investing platform!


Health Care


Dr Paul Gavin



Market Capitalisation


Price-earnings ratio


Dividend yield


High today


Low today


Open price


52-week high


52-week low



What does Avecho Biotechnology Limited (AVE) do?

Health products for humans and animals. But mostly humans. 

Avecho Biotechnology Limited is a Melbourne-based biotechnology company. The majority of its products are in development, but the basis of them all is its proprietary TPM (Tocopherol Phosphate Mixture) drug delivery system. TPM is a derivative of Vitamin E and “is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients”.

Avecho’s current priority for the human health market is to finalise the development of its Cannabidiol (CBD) soft-gel product, and the supporting Chemistry, Manufacturing and Control (CMC) work required for approval by the Therapeutic Goods Administration (TGA) or U.S. Food and Drug Administration (FDA). Another focus is developing products that enhance livestock feeding efficiency and health.

In October 2021, Avecho announced a collaboration with the Lambert Initiative, a long-term research program at the University of Sydney exploring the potential of cannabis in medications.

How does Avecho Technology make money?

Avecho operates in three business segments: Production, Human Health and a segment called All Other.

The Production segment sees revenue primarily from the manufacturing and sale of TPM and another TPM based product, Vital ET. Sales are made at a fixed fee per kilogram to a specialty chemical company, Ashland, for use in the global personal care industry.

As the majority of Avecho’s products are still in development, the company does not earn revenue from the Human Health and All Other segments at this time.

Is Avecho Biotechnology a profitable company?

No, the company is not profitable at this time. 

Since FY2012, the company has only recorded net losses, with FY2019’s positive income of A$849.96k being the exception. In FY2020 and FY2021, Avecho recorded net losses of A$2.63m and A$3.42m, respectively.

Avecho has continued to operate by issuing more shares and options. In February 2021, the company issued A$4.765m worth of stock at A$0.022 per share to “sophisticated investors.” It also issued 115m listed options to the same investors as well as 7.5m more listed options to the brokers.

As of April 2022, the company holds A$3.265m of cash on its books.

Is AVE stock a buy?

On 1 March 2022, the company announced the commencement of patient dosing to examine if its topically applied CBD can relieve the symptoms of osteoarthritis. 

By the end of the month, the company announced positive results with the study demonstrating “significant improvements in hand pain, hand functionality, grip strength, finger stiffness and anxiety”.

Consequently, the AVE stock price skyrocketed almost 65% from A$0.013 to A$0.02 but by the end of April had dropped off 15% to A$0.017.

As the company has a history of poor earnings, some investors would argue AVE stock makes a good speculative short-term trade but not a long-term investment.

Does AVE stock pay dividends?

Avecho Biotechnology paid dividends back in FY2009 and FY2010 but has not since then. The company has not made any announcements to do so for this financial year or the future.

Who owns AVE stock?

Holding 67.2% of the total float, the general public owns the majority of AVE stock. Individual insiders hold 21.9%.

AVE stock’s biggest owners include Mark Kerr (8.52%), Ross Copeland (5.04%), Melbourne Securities Corporation Ltd (3.23%), Paradyce Pty. Ltd (2.1%), Servbond Pty Ltd (1.31%), ACK Pty Ltd (1.12%), Wayne Kent (1.09%), Tony Amato (1.06%) and Churchcourt Pty Limited (1.04%).

Individual insiders with the most significant holdings include Chief Operating Officer Roksan Libanaki (0.6%), Chief Executive Officer Paul Gavin (0.59%), Chairman Gregory Collier (0.11%) and Non-Executive Director Ross Murdoch (0.091%).

How do I buy AVE stock?

Stake offers a quick and easy way to purchase AVE shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is CHESS sponsored, meaning that when you invest in Australian shares, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding AVE, sign up today.

Ready to start your investing journey with Stake?

Open an account


Yes, the Stake platform allows you to buy AVE shares and over 12,000 stocks and ETFs across the ASX and Wall St.

One share of Avecho Biotechnology Limited is valued at $0.00.

The ticker symbol for Avecho Biotechnology Limited is AVE.

To buy AVE stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake AUS
  3. Deposit directly into your Stake wallet and you're ready to invest in AVE

The Avecho Biotechnology Limited 52-week high stock price is $0.01.

The Avecho Biotechnology Limited 52-week low stock price is $0.00.

As of 24/06/2024 Avecho Biotechnology Limited has a market cap of $10M.

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in AVE
on Stake

Buy AVE from AU$3 brokerage

Invest in 2,500+ Aussie stocks and ETFs

CHESS-sponsored ASX trades

Get started
Canstar award phone
AVE related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.